

# Peter J Bailey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2805274/publications.pdf>

Version: 2024-02-01

19  
papers

9,227  
citations

567144

15  
h-index

887953

17  
g-index

19  
all docs

19  
docs citations

19  
times ranked

15005  
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 875836.	1.8	0
2	Perioperative immunotherapy for pancreatic cancer is on its way. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 534-537.	0.7	2
3	Clinical Impact of Molecular Subtyping of Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743908.	1.8	29
4	Using Chromatin Accessibility to Delineate Therapeutic Subtypes in Pancreatic Cancer Patient-Derived Cell Lines. <i>STAR Protocols</i> , 2020, 1, 100079.	0.5	6
5	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.	2.9	78
6	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 38, 198-211.e8.	7.7	99
7	PDAC Subtypes/Stratification. <i>Molecular and Translational Medicine</i> , 2020, , 117-128.	0.4	1
8	Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. <i>Cancer Research</i> , 2019, 79, 5316-5327.	0.4	36
9	CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. <i>Cell Reports</i> , 2018, 23, 1448-1460.	2.9	169
10	BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1021-1026.	2.9	61
11	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2017, 32, 185-203.e13.	7.7	1,428
12	Hypermutation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	0.6	174
13	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 35848.	1.6	127
14	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2016, 29, 832-845.	7.7	645
15	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	13.7	2,700
16	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. <i>Journal of Pathology</i> , 2015, 237, 363-378.	2.1	98
17	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015, 521, 489-494.	13.7	1,206
18	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	13.7	2,132

#	ARTICLE	IF	CITATIONS
19	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nature Communications, 2014, 5, 5224.	5.8	236